30 results on '"Guzman-Becerra, Norma"'
Search Results
2. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
3. P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)
4. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant
5. Exploring the Impact of Humoral Immunogenicity with Tabelecleucel (Tab-cel) for the Treatment of Epstein–Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Hematopoietic Stem Cell Transplantation (HCT) and Solid Organ Transplantation (SOT)
6. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R+CT) (ALLELE)
7. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
8. Exploring the Impact of Humoral Immunogenicity with Tabelecleucel for the Treatment of EBV+ PTLD Following HCT and SOT
9. Clinical Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study
10. Clinical Experience of Tabelecleucel in Patients with Life-Threatening Complications of Epstein–Barr Virus Viremia
11. Clinical Experience of Tabelecleucel in Patients with EBV+ Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease
12. A Multicenter, Multicohort, Open-Label, Single Arm per Cohort, Phase II Study to Assess the Efficacy and Safety of Tabelecleucel in Patients with EBV-Associated Diseases Using an Adaptive Two-Stage Study Design
13. 200 - Exploring the Impact of Humoral Immunogenicity with Tabelecleucel (Tab-cel) for the Treatment of Epstein–Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Hematopoietic Stem Cell Transplantation (HCT) and Solid Organ Transplantation (SOT)
14. 25 - New and Updated Results from a Multicenter, Open-Label, Global Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R+CT) (ALLELE)
15. Self-reported oral health of enrollees in capitated and fee-for-service dental benefit plans
16. Self-reported satisfaction of enrollees in capitated and fee-for-service dental benefit plans
17. Correlation of Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel with response and survival in rituximab relapsing or refractory EBV+ post-transplant lymphoproliferative disease (PTLD).
18. Do People with HIV Get the Dental Care They Need? Results of the HCSUS Study
19. Self-Reported Behavior and Attitudes of Enrollees in Capitated and Fee-for-Service Dental Benefit Plans
20. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
21. A longitudinal analysis of unmet need for oral treatment in a national sample of medical HIV patients
22. 532 - A Multicenter, Multicohort, Open-Label, Single Arm per Cohort, Phase II Study to Assess the Efficacy and Safety of Tabelecleucel in Patients with EBV-Associated Diseases Using an Adaptive Two-Stage Study Design
23. 223 - Clinical Experience of Tabelecleucel in Patients with Life-Threatening Complications of Epstein–Barr Virus Viremia
24. 219 - Clinical Experience of Tabelecleucel in Patients with EBV+ Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease
25. Exploring the Impact of Humoral Immunogenicity with Tabelecleucel (Tab-cel) for the Treatment of Epstein–Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+PTLD) Following Hematopoietic Stem Cell Transplantation (HCT) and Solid Organ Transplantation (SOT)
26. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R+CT) (ALLELE)
27. Exploring the Impact of Humoral Immunogenicity with Tabelecleucel for the Treatment of EBV+PTLD Following HCT and SOT
28. Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).
29. Oral white patches in a national sample of medical HIV patients in the era of HAART
30. Clinical Experience of Tabelecleucel in Patients with EBV+Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.